Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease

NCT04369183 · clinicaltrials.gov ↗
COMPLETED
Status
25
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

Istanbul University